Sativex® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: Basic features and main clinical data

Expert Review of Neurotherapeutics

Volumn 11, Issue 4 SUPPL. 1, 2011, Pages 15-19

  Vermersch, Patrick ^a  

^a UNIV LILLE   (France)

Author keywords

endocannabinoid system; multiple sclerosis; quality of life; Sativex ; spasticity

Indexed keywords

CANNABIS;

ADD ON THERAPY; CONFERENCE PAPER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FATIGUE; HUMAN; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SINGLE BLIND PROCEDURE; SOMNOLENCE; SPASTICITY;

CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PLANT EXTRACTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79953826032     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.27     Document Type: Conference Paper

References (15)

1. Russo EB. Cannabinoids in the management of diffcult to treat pain. Ther. Clin. Risk Manag. 4, 245-249 (2008).
2. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int. J. Clin. Pract. 59, 291-295 (2005). (Pubitemid 40352745)
3. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler. 12, 646-651 (2006). (Pubitemid 46940639)
4. Pérez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today 42, 495-501 (2006).
5. Stott CG, Wright S, Guy GW. A comparison of pharmacokinetic profles of inhaled?-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans: implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol. 15(Suppl. 3), 365 (2008).
6. Potter DJ, Clark P, Brown MB. Potency of 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 53, 90-94 (2008). (Pubitemid 351239216)
7. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 66, 234-246 (2006). (Pubitemid 41773895)
8. Collin C, Davies P, Mutiboko IK, Ratcliffe S; for the Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14, 290-296 (2007). (Pubitemid 46384865)
9. Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32, 451-459 (2010).
10. Novotna A, Mares J, Ratcliffe S et al. Arandomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. DOI: 10.1111/j.1468-1331.2010.03328.x (2011) (Epub ahead of print).
11. Montalbán X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Mult Scler. 15, S272 (2009).
12. Wade D, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specifc effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10, 434-441 (2004). (Pubitemid 39117341)
13. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12, 639-645 (2006). (Pubitemid 46940638)
14. Collin C, Serpell M, Potts R. Results of an open-label extension trial of Sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity. Mult Scler. 13, S129 (2007).
15. Schoedel K, Chen N, Guy GW et al. Abuse potential of nabiximols oromucosal spray compared with dronabinol and placebo in recreational marijuana users. Eur. Neuropsychopharmacol. 20(Suppl. 3), S587 (2010).